Labs and Industry Stakeholders Respond to FDA LDT Rule
Explore the response to the FDA's Laboratory Developed Tests, LDTs, final rule, including industry concessions, legal challenges, and legislative reactions.
Stay updated with breaking news from Clinical Laboratory Evaluation Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Explore the response to the FDA's Laboratory Developed Tests, LDTs, final rule, including industry concessions, legal challenges, and legislative reactions.
The U.S. Food and Drug Administration (FDA or the Agency) issued a Final Rule on May 6, 2024 (89 FR 37286), that will, over the next four years, radically alter the landscape...
The U.S. Food and Drug Administration (FDA or the Agency) issued a Final Rule on May 6, 2024 (89 FR 37286), that will, over the next four years, radically alter the landscape for...
On May 6, 2024, the U.S. Food and Drug Administration issued its final rule significantly modifying FDA's approach to oversight of laboratory developed tests.
New rule creates premarket review, reporting, quality system, and other requirements for laboratory developed tests...